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The characterization of molecular changes in diseased tissues gives insight into
pathophysiological mechanisms and is important for therapeutic development. Genome-
wide gene expression analysis has proven valuable for identifying biological processes
in neurodegenerative diseases using post mortem human brain tissue and numerous
datasets are publically available. However, many studies utilize heterogeneous tissue
samples consisting of multiple cell types, all of which contribute to global gene
expression values, confounding biological interpretation of the data. In particular,
changes in numbers of neuronal and glial cells occurring in neurodegeneration
confound transcriptomic analyses, particularly in human brain tissues where sample
availability and controls are limited. To identify cell specific gene expression changes
in neurodegenerative disease, we have applied our recently published computational
deconvolution method, population specific expression analysis (PSEA). PSEA estimates
cell-type-specific expression values using reference expression measures, which in the
case of brain tissue comprises mRNAs with cell-type-specific expression in neurons,
astrocytes, oligodendrocytes and microglia. As an exercise in PSEA implementation and
hypothesis development regarding neurodegenerative diseases, we applied PSEA to
Parkinson’s and Huntington’s disease (PD, HD) datasets. Genes identified as differentially
expressed in substantia nigra pars compacta neurons by PSEA were validated using
external laser capture microdissection data. Network analysis and Annotation Clustering
(DAVID) identified molecular processes implicated by differential gene expression in
specific cell types. The results of these analyses provided new insights into the
implementation of PSEA in brain tissues and additional refinement of molecular signatures
in human HD and PD.
Keywords: computational deconvolution, Huntington’s disease, Parkinson’s disease, autophagy, microarray,
transcriptomic analysis
INTRODUCTION
Identifying changes in gene or protein expression has the poten-
tial to focus attention on key molecular mechanisms underlying
a given degenerative process (e.g., disease or aging effects on
the brain). Genome wide expression studies using microarrays
and next generation sequencing (NGS) technologies have been
widely adopted to identify gene expression changes in human
post mortem tissue for a number of neurodegenerative diseases.
However, neurodegenerative diseases often lead to progressive
changes in brain parenchyma composition, typically compris-
ing a decline in the number of neuronal cells, together with an
increase of glial cell number (astrocytes, oligodendrocytes and/or
microglia) (Figure 1). These changes in the relative proportions
of different cell populations can confound the ability to detect
the molecular changes occurring in specific cell types. Therefore,
when analyzing genome wide expression data from central ner-
vous system (CNS) tissues it is important to use methods that
can reliably account for changes in cell numbers to allow correct
interpretations.
To overcome this problem, we have recently developed a
method called Population-Specific Expression Analysis (PSEA)
and shown its potential to successfully identify novel gene
expression changes in human HD caudate (Kuhn et al., 2011).
The method deconvolves brain expression heterogeneity by lin-
ear regression modeling to resolve cell-type-specific expression
changes. We therefore reasoned that implementation of PSEA
has the potential to create new, improved analyses of other brain
datasets describing neurodegenerative processes.
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FIGURE 1 | (A) Schematic representation of brain tissue atrophy
concomitant with the progression of neurodegenerative disease; (B)
Representation of the typical changes in the numbers of specific brain cell
subtypes (neurons, oligodendrocytes, microglia and astrocytes) during
disease, based on histopathological studies (Vonsattel et al., 2011). Of note,
neuronal loss (atrophy and/or decrease in number) is accompanied by
gliosis (increases in numbers of astrocytes, oligodendrocytes and/or
microglia). The relative changes in specific glial subtypes vary by disease,
however.
Here we applied the PSEA method on publically avail-
able genome wide expression data generated from human
Huntington’s disease (HD) motor cortex (Hodges et al., 2006)
as well as Parkinson’s disease (PD) datasets derived from human
prefrontal cortex, putamen and substantia nigra tissues (Zhang
et al., 2005). Differentially expressed genes were analyzed for
their inclusion in co-regulated gene networks, protein-protein
interactions (PPIs) and memberships within identified func-
tional networks to identify biological processes that may underlie
disease-related effects. These analyses reinforced the robustness
of the method and identified potential genes and pathways for
further study.
MATERIALS AND METHODS
MICROARRAY GENE EXPRESSION DATA
In the present study, we applied PSEA and standard differential
expression analyses to HD brain mRNA expression data from
frontal cortex (BA4) samples (16 control and 18 HD brains)
(Hodges et al., 2006), and to PD brain expression data from
prefrontal cortex (15 control and 14 PD), substantia nigra (18
control and 11 PD) and putamen (15 control and 20 PD) (Zhang
et al., 2005). Microarray data sets were downloaded from Gene
Expression Omnibus (Barrett et al., 2013) (GSE3790 for HD and
GSE20295 for PD) (http://www.ncbi.nlm.nih.gov/geo/). These
data were generated on Affymetrix Human microarrays U133A
(HD, PD) and U133B (HD only). Probesets were annotated with
current HUGO Gene Nomenclature Committee (HGNC) gene
assignments using bioDBnet (Mudunuri et al., 2009) (http://
biodbnet.abcc.ncifcrf.gov/db/db2db.php#biodb).
PSEA ANALYSES
For a comprehensive review on the implementation of PSEA, see
(Kuhn et al., 2015) and the PSEA R package (www.bioconductor.
org). The initial step in the application of PSEA to the datasets
was to select appropriate marker gene probesets for each brain cell
population (neurons, astrocytes, oligodendrocytes andmicroglia)
(Kuhn et al., 2011, 2012). Marker genes were selected based upon
prior evidence of cell-type-restricted expression in the literature
and previous implementation of PSEA in HD (Kuhn et al., 2011).
We verified that the signals corresponding to different probesets
representing the same cell population were highly correlated
(mean correlation >0.5), and conversely, that the signals of the
marker gene probesets representing the other cell populations
were poorly correlated (mean correlation <0.05). The probesets
used as reference expression signals for each cell type and dataset
were as follows. For HD BA4 cortex, neurons: 221805_at (NEFL),
221801_x_at (NEFL), 221916_at (NEFL), 201313_at (ENO2),
210040_at (SLC12A5), 205737_at (KCNQ2), 210432_s_at
(SCN3A); astrocytes: 203540_at (GFAP), 210068_s_at (AQP4),
210906_x_at (AQP4), 201667_at (GJA1), oligodendrocytes:
211836_s_at (MOG), 214650_x_at (MOG), 216617_s_at
(MAG), 207659_s_at (MOBP), 207323_s_at (MBP), 209072_at
(MBP); and microglia: 204192_at (CD37), 215051_x_at (AIF1),
209901_x_at (AIF1), 213095_x_at (AIF1). For PD prefrontal
cortex, neurons: 221805_at (NEFL), 221801_x_at (NEFL),
221916_at (NEFL), 201313_at (ENO2), 210040_at (SLC12A5),
205737_at (KCNQ2); astrocytes: 203540_at (GFAP), 210068_s_at
(AQP4), 210906_x_at (AQP4), 201667_at (GJA1); oligodendro-
cytes: 211836_s_at (MOG), 214650_x_at (MOG), 216617_s_at
(MAG), 207323_s_at (MBP), 209072_at (MBP); and microglia:
215051_x_at (AIF1), 209901_x_at (AIF1), 213095_x_at (AIF1).
For PD substantia nigra and putamen, neurons: 221805_at
(NEFL), 221801_x_at (NEFL), 221916_at (NEFL), 201313_at
(ENO2), 210040_at (SLC12A5), 205737_at (KCNQ2); astrocytes:
203540_at (GFAP), 210068_s_at (AQP4), 210906_x_at (AQP4),
201667_at (GJA1); oligodendrocytes: 211836_s_at (MOG),
214650_x_at (MOG), 216617_s_at (MAG), 207323_s_at (MBP),
209072_at (MBP); microglia: 215051_x_at (AIF1), 209901_x_at
(AIF1), 213095_x_at (AIF1).
To calculate the reference expression signals for each cell
type we proceeded as follows. First, the expression values of the
selected probesets were normalized to an average value of 100
to give them an equal weight, and those reporting the same
marker gene expression were then averaged to obtain a marker
gene expression measure for each gene. Then we averaged the
marker gene expression measures for each cell population to
obtain a reference expression signal for each cell population for
each sample.
The next step was to fit candidate multiple regression models
for the data for all probesets. Using the Akaike information cri-
terion (AIC) (Akaike, 1974), we selected the best model for each
probeset in terms of the regressors to be included from the set
of reference signals corresponding to the 4 cell populations con-
sidered. In this way, we obtained models with 1–4 regressors that
were then tested for quality of fit. The criteria used were the fol-
lowing: F-test (p < 0.05), adjusted R squared >0.6 and Shapiro
test for a Gaussian distribution of the residuals (p > 0.01). In
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addition, models with large intercepts (absolute value larger than
half of the mean expression value of the probeset) or nega-
tive coefficients were excluded. The probesets comprising the
reference expression signals were also removed from the final
tables.
In order to test for differential expression between control and
disease samples we added one auxiliary regressor to each of the
selected models. This regressor was formed by a vector having
zeros in all positions except for the ones of the disease samples
corresponding to the interrogated cell type. The auxiliary regres-
sors were added one at a time to assess the specific expression of
each cell type included in themodel. For each cell type, the regres-
sor coefficient represents the specific expression in the control
group, while the coefficient of the auxiliary regressor estimates the
differential expression and the specific expression in the disease is
determined as the sum of both. The quality of the models includ-
ing the auxiliary variable was then re-assessed as explained above.
Finally, we constructed a table showing the multiple regression
results of the probesets ordered by the p-values of the differen-
tial expression, including only cases with p < 0.05. The PSEA was
implemented using a customized R script (Gentleman et al., 2004)
using the functions lm and stepAIC.
An alternative approach to select the multiple regression mod-
els was applied in tissues where the simultaneous modeling of
expression in the four cell types was hampered by poor correla-
tions of the expression reported by the astrocyte and oligodendro-
cyte reference probesets (see below). In these cases, we restricted
our analyses to probesets that reported expression exclusively in
a single cell type, so as to avoid misassignment of differential
expression. Single cell type expression was assigned by computing
the correlation between each probeset and the reference signals
and restricting further analyses to the cases where the correla-
tion was larger than 0.8 for a single cell type (e.g., neurons)
and less than 0.2 for the other three cells types (e.g., astrocyte,
oligodendrocyte and microglia). We then calculated regressions
with only one cell-type regressor (neurons in the above example)
plus the corresponding auxiliary regressor (for differential expres-
sion between disease and control). The models obtained in this
way were tested for quality of fit in the same manner explained
above for the models selected with AIC, and tables to show the
differential expression results were constructed. This approach
proved useful in cases where the probes typically used to create
the reference expression signals showed poor correlation between
them (as was observed for astrocyte and oligodendrocyte signa-
tures in the PD substantia nigra and putamen data sets) because
it allowed us to nonetheless apply the PSEA to the cell types
that have good quality reference expression signals (neurons and
microglia in this example). The disadvantage of this approach is
that we are unable to make interpretations regarding the differ-
ential expression of genes that are expressed in multiple cell types
or in the cell types with poorly correlated probesets comprising
the reference expression signals (here, astrocytes and oligoden-
drocytes). As a way to validate the approach, we compared the
performance of both strategies in selecting models using PD
prefrontal cortex, which has good reference signals and a large
number of differentially expressed genes. This showed that 70%
of the differentially expressed probes identified by the standard
implementation of PSEA were also detected using the alternative
approach.
STANDARD GENE EXPRESSION ANALYSIS
In order to evaluate the potential for PSEA to refine gene expres-
sion measures, we compared PSEA results to standard differential
expression analyses performed with packages from Bioconductor
(affy (Gautier et al., 2004) and limma (Smyth, 2005)) (www.
bioconductor.org). HD cortex analysis with limma identified
1925 differentially expressed (DE) probesets passing a fdr cutoff
of p < 0.05, consistent with our previous analysis of these data
(Hodges et al., 2006). For PD cortex, limma analysis identified 304
DE probesets passing a fdr cutoff of p < 0.05, whereas 91 probe-
sets showed differential expression in the substantia nigra and
only 1 probeset in the putamen by the same significance threshold
criterion.
VALIDATION OF PSEA ASSIGNMENT USING CELL SPECIFIC
EXPRESSION DATA
Two independent, publically available genome-wide expression
data sets examining mouse CNS cell type gene expression were
used to evaluate PSEA-based expression predictions. These two
datasets examined relative expression in three of the four CNS
cell types examined in our the PSEA analyses (neurons, oligoden-
drocytes, astrocytes). One of the datasets employed subcultures of
primary mouse brain cells to derive cell-type-specific expression
profiles (Cahoy et al., 2008), of which we used profiles of postna-
tal day 16 neurons, postnatal day 17 astrocytes, and myelinating
oligodendrocytes. The second data set employed translating ribo-
some affinity purification (TRAP) to mouse brain tissue to gen-
erate cell-type-specific expression profiles of different CNS cell
types (Doyle et al., 2008), of which we used Ntsr1-positive cor-
tical neurons, Aldh1L1-positive cortical astrocytes, and Cmtm5-
positive cortical oligodendrocytes. Both datasets were generated
using the Affymetrix Murine 430 plus 2.0 microarray platform.
To compare our PSEA-based expression predictions from human
tissues to the mouse data, murine probesets were annotated with
current corresponding HGNC gene assignments using dbOrtho
tool in bioDBnet (Mudunuri et al., 2009) and the list of probesets
for which PSEA achieved suitable expression models (Tables S1,
S2) were reduced to unique HGNC ids. Then for each assignment
of expression in a particular cell type by PSEA, we tallied whether
expression was detected in that cell type in the mouse datasets,
using a threshold of>100 arbitrary normalized expression units.
VALIDATION OF PSEA DIFFERENTIALLY EXPRESSED GENES IN PD
SUBSTANTIA NIGRA
PSEA results of DE in PD substantia nigra neurons were vali-
dated using additional microarray expression data. These data
were published in three independent studies that used laser cap-
turemicrodissection (LMD) to selectively sample substantia nigra
neurons; the tissue samples in these studies were comparable in
terms of patient cohort age and disease state to the samples used
in the PSEA analysis. For each of the 8 genes identified as dif-
ferentially expressed in substantia nigra by PSEA (p < 0.05) we
determined if the gene was identified as significantly changed in
the same direction in any of the three LMD data sets. For two
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of the LMD studies (Simunovic et al., 2010; Elstner et al., 2011)
fold change and p-values from microarray gene expression analy-
ses available as supplementary data with the original manuscript
were used for comparison. DE results were not published for the
third LMD data set (Middelton-1 dataset included in Zheng et al.,
2010); therefore the raw microarray data was downloaded from
Gene Expression Omnibus (accession number GSE20141) and
we performed differential expression analyses by standard limma
analysis to obtain the necessary statistics (Smyth, 2005). LMD
p-values and fold changes for all three studies are tabulated for
comparison against PSEA-determined values.
FUNCTIONAL ANNOTATION CLUSTERING
The David 2.0 Bioinformatics database was used to identify func-
tionally related groups of DE genes in individual cell types (http://
david.abcc.ncifcrf.gov/) (Huang Da et al., 2009; Sprooten et al.,
2014). Panther and Reactome pathways were added to the default
selected functional annotation and the functional annotation
clustering tool was applied to the lists of probe sets. The classi-
fication stringency setting used was medium with default setting
for function grouping except for enrichment thresholds for EASE
which were reduced to 0.05 to reduce inclusion of non significant
terms into the clusters. Annotation Clusters of significantly over
represented groups with terms having a FDR<50%were accepted
for further consideration.
NETWORK ANALYSIS
Cytoscape was used to examine coregulation, cell type specific
expression and PPI networks for DE genes. A HGNC database
was downloaded in July 2014 (Gray et al., 2013) (http://www.
genenames.org/) and imported into Cytoscape 2.8.3 (http://www.
cytoscape.org/) (Smoot et al., 2011). Using HGNC gene sym-
bols as the key ID, the HGNC network was then merged with a
network of coregulated gene pairs computed from seven normal
human cortex data sets (Mistry et al., 2013). Human PPIs for DE
genes (proteins) within the selected network were retrieved from
Biogrid on August 17th 2014 (http://thebiogrid.org/) (Stark et al.,
2006). Publically available genome wide gene expression data of
mouse CNS cell types was obtained as supplementary data (Doyle
et al., 2008) and mapped onto the HGNC network after retriev-
ing the current corresponding HGNC gene assignments using
dbOrtho tool in bioDBnet (Mudunuri et al., 2009). Cytoscape
App Multicolored nodes (Warsow et al., 2010) was employed
to visualize cell specific expression data in specific molecular
networks.
RESULTS AND DISCUSSION
The present analyses comprise a study in the implemen-
tation of PSEA within the International Neuroinformatics
Coordinating Facility (INCF) Short Course on Neuroinformatics,
Neurogenomics and Brain Disease held in 2013 (https://sites.
google.com/site/neuroinformaticsjamboree), with a view toward
assessing candidate mechanisms of human neurodegenerative
diseases. The datasets used in the analyses presented here are pub-
lically available and derived from postmortem samples of human
HD (Hodges et al., 2006) and PD brains (Zhang et al., 2005)
(see Materials and Methods). These two conditions represent two
functionally distinct disease-related perturbations to the motor
output circuit involving the cerebral cortex and basal ganglia
(Albin et al., 1989).
HD is an autosomal dominantly inherited neurodegenerative
disorder caused by a CAG repeat expansion in the Huntingtin
(HD, ITI5) gene (The Huntingtons Disease Collaborative
Research Group, 1993). The CAG repeat expansion encodes a
polyglutamine stretch within the N-terminal domain of the hunt-
ingtin protein (Htt) that imparts neurotoxicity, mostly through
gain-of-function mechanisms, including Htt protein aggregation,
as has been recapitulated in animal studies (Bates et al., 2002).
A recent report using the PSEA method corroborated previous
mouse data by detecting myelin-related gene expression changes
in HD oligodendrocytes, supporting the possibility that deficient
myelin synthesis and/or composition changes may by drivers of
disease in HD (Kuhn et al., 2011).
PD is a neurodegenerative disease that can have either a spo-
radic or a familial etiology (Block et al., 2007). PD is typified
by specific loss of dopaminergic neurons of the substantia nigra
pars compacta that project to the neostriatum (caudate nucleus
and putamen) (Dickson, 2012). This degeneration leads to PD-
related symptoms including bradykinesia, tremor, rigidity and
postural instability (Dauer and Przedborski, 2003). At the cel-
lular level, PD is characterized by α-synuclein protein aggregates
in neuronal cells (also known as Lewy bodies). Genes associated
with familial PD include the gene encoding α-synuclein (SNCA)
and genes involved in protein turnover and mitochondrial home-
ostasis, such as PARK2, which encodes Parkin (Kumar et al.,
2012).
IMPLEMENTATION OF PSEA TO IDENTIFY DIFFERENTIAL EXPRESSION
WITHIN SPECIFIC CELL SUBPOPULATIONS IN HD AND PD BRAINS
In the present study, we applied PSEA analyses to expression data
derived from motor cortex (BA4) samples from 16 control and
18 HD brains, and to prefrontal cortex samples from 15 control
and 14 PD brains. For these cortical samples, the PSEA expres-
sion models were selected with the approach described in (Kuhn
et al., 2011; see Materials and Methods) to assign expression and
analyze differential expression using a model representing four
cell compartments (neurons, astrocytes, oligodendrocytes and
microglia). The regressors used for each of these models are listed
in Supplementary Tables S1, S2. For HD motor cortex, PSEA
provided evidence of 14 genes differentially expressed in neu-
rons, 6 in astrocytes, and 8 in oligodendrocytes (0 in microglia)
(Table S3). For PD prefrontal cortex, PSEA identified differen-
tial expression of 122 genes in neurons, 5 in astrocytes, 11 in
oligodendrocytes, and 11 in microglia (Table S4). There was very
little overlap between the genes identified as DE in HD and PD
cortex but, interestingly, both diseases shared down regulation
of doublecortin-like kinase 1 (DCLK1), a multi-functional, neu-
ronally expressed gene known to be involved in neuronal migra-
tion, retrograde transport, neuronal apoptosis and neurogenesis
(Dijkmans et al., 2010).
When the same PSEA procedures were applied to the PD sub-
stantia nigra (18 control and 11 PD) and putamen (15 control and
20 PD) datasets, we observed that the expression signals for the
probesets that we had previously used to represent astrocytes and
oligodendrocytes did not exhibit good correlation. Therefore, an
alternative approach was adopted to select the multiple regression
Frontiers in Neuroscience | Neurogenomics January 2015 | Volume 8 | Article 441 | 4
Capurro et al. PSEA deconvolution
models that could be fit to a single cell type (neurons or microglia
only), to avoid relying on reference signals with poor correlations
(see Materials and Methods). These analyses provided evidence
for the differential expression of 8 genes in neurons in the sub-
stantia nigra (Table S5) and 11 genes in neurons in the putamen
(Table S6). Interestingly, however, DCLK1 was again one of the
genes identified as differentially expressed in neurons in the sub-
stantia nigra, and was thus detected as differentially expressed in
three of four neuronal datasets.
EXTERNAL VALIDATION OF ASSIGNMENT OF CELLULAR EXPRESSION
We used publically available genome wide expression datasets
to validate PSEA-based expression assignments. Comprehensive
cell type expression data generated from human cells was not
available so expression data from mouse models were used (see
Materials and Methods Section “Validation of PSEA Assignment
using Cell Specific Expression Data”). We were able to corrobo-
rate PSEA-assigned expressions for a very large fraction of genes
for which a suitable four-cell-type expression model could be
constructed (Table 1).
COMPARISON OF PSEA AND STANDARD DIFFERENTIAL EXPRESSION
ANALYSES
We subsequently compared the outputs of population-specific
and standard expression analyses (limma) to assess the potential
improvement of cellular resolution of DE using PSEA. (For refer-
ence, results of the limma analyses of the datasets are included
as Table S7.) Example comparisons from the analyses of PD
frontal cortex and substantia nigra are illustrated in Figure 2.
In the left panels for each gene (mRNA) their neuron-assigned
expression values are plotted against the neuron reference expres-
sion signals to visualize disease-related expression differences
in the slopes of the linear regressions fitted to the individ-
ual sample datapoints (black for control, red for PD). The
accompanying box plots show the uncorrected expression val-
ues (from limma). These plots indicate examples that distinguish
true differential expression from the reduction in the overall
numbers of neuronal cells [SV2B (Figure 2K)], cases where
PSEA detects differential expression when standard analyses were
equivocal [PPP3CB (Figure 2A), GUCY1B3 (Figure 2B), RGS7
(Figure 2C), SYNJ1 (Figure 2E), DNM3 (Figure 2G), NDUFS2
(Figure 2H), RGS4 (Figure 2I), DCLK1 (Figure 2 J)] and exam-
ples where limma would mis-assign the trend for differential
expression as decreased rather than increased in diseased vs.
control neurons [LPCAT1 (Figure 2D), PAK7 (Figure 2F), and
INPP5F (Figure 2L)].
COMPARISON OF DE GENES IN SUBSTANTIA NIGRA WITH LASER
CAPTURE MICRODISSECTION DATA
Due to the strong interest in the effect of PD on neuronal gene
expression in the substantia nigra pars compacta, a number of
independent data sets have been published using LMD to obtain
neuron-specific microarray expression profiles from postmortem
human tissue. Although LMD cannot entirely replicate the PSEA
analysis because it is limited to sampling RNA profiles in the cell
body, whereas neuronal RNAs can be transported from the soma
for local translation in both dendrites and axons, it is nonetheless
the most appropriate data available for comparison. Despite this
limitation, 6 out of 8 genes detected as differentially expressed in
substantia nigra neurons by PSEA (Table S5) were validated as DE
in the same direction in at least 1 independent LMD PD study.
Furthermore, 4 out of 8 DE genes were validated in 2 indepen-
dent studies (Table 2). These data further support the accuracy of
prediction of cellularly resolved DE by PSEA.
The genes identified by PSEA as decreased in expression in
PD substantia nigra, and validated by independent LMD stud-
ies, namely, chimerin 1 (CHN1) N-ethylmaleimide-sensitive fac-
tor (NSF), Synaptic Vesicle Glycoprotein 2B (SV2B), GABA(A)
receptor-associated protein like 1 (GABARAPL1), the proton-
transporting lysosomal 70kDa protein ATPase subunit V1 sub-
unit A (ATP6V1A), and DCLK1 comprise potential candidates
for further investigation. The synaptic vesicle-associated protein
encoded by NSF has been recently highlighted in another bioin-
formatics screen aimed at identifying novel therapeutic targets
for PD that included a meta analysis of transcriptomic data
(Karic et al., 2011). In addition, a recent GWAS study identified
Table 1 | Supporting evidence for gene expression in specific cell types from publically available datasets.
Disease Cell type Number of Number of unique Mouse HGNC homologs with
dataset regressor probe sets HGNC IDS expression >100
Primary culture expression TRAP expression
(Cahoy et al., 2008) (Doyle et al., 2008)
Huntington’s
disease cortex
Neuron 282 267 81% (210/259) 75% (193/259)
Astrocyte 60 54 84% (43/51) 73% (37/51)
Oligodendrocyte 194 179 80% (139/174) 66% (115/174)
Parkinson’s
disease cortex
Neuron 261 254 78% (188/239) 70% (167/239)
Astrocyte 89 88 75% (62/83) 64% (64/83)
Oligodendrocyte 68 65 67% (40/60) 53% (32/60)
PSEA assignments of gene expression in neurons, astrocytes and oligodendrocytes were verified using two independent, publically available mouse expression
datasets (Cahoy et al., 2008; Doyle et al., 2008). For procedures, see Materials and Methods, Section Validation of PSEA assignment using cell specific expression
data.
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FIGURE 2 | Comparison of PSEA-derived expression changes (left panels,
regression plots) and standard gene expression measures (right panels,
bar graphs) in PD (Control samples shown in black, PD samples in red).
(A–J) Neuronal expression in PD prefrontal cortex. (K,L) Neuronal expression
in PD substantia nigra. For each probeset (mRNA/gene) we present 2 panels
showing its neuron-assigned expression plotted against the neuron reference
expression signal for each sample (where the differential expression can be
visualized by the difference in slopes, left panels) and box plots directly
comparing the expression values (right panels). PSEA statistics for each gene
can be found in Table S4. Limma statistics for each gene are as follows. A: log
fold change= −0.862, p = 0.011, FDR p-value 0.145,B: log fold change= −1.1,
p = 0.002, FDR p-value = 0.07, C: log fold change = −1.184, p = 0.002, FDR
p-value = 0.078,D: log fold change = −0.034, p = 0.822, FDR p-value = 0.914,
E: log fold change = -1.449, p = 0.005, FDR p-value = 0.103, F: log fold
change = 0.065, p = 0.785, FDR p-value = 0.895, G: log fold change = −0.71,
p = 0.043, FDR p-value = 0.245, H: log fold change = −0.388, p = 0.054, FDR
p-value = 0.268, I: log fold change = −1.249, p = 0.011, FDR p-value = 0.144,
J: log fold change = −1.272, p = 0.008, FDR p-value = 0.125, K: log fold
change = −1.325, p = 0.0002, FDR p-value = 0.049, L: log fold
change = −0.409, p = 0.231, FDR p-value = 0.646.
Table 2 | Validation of PSEA determined DE in neurons in substantia nigra in PD by comparision with three independent LMD studies.
Gene symbol PSEA analysis this study Simunovic et al., 2010 Elstner et al., 2011 Zheng et al., 2010
p-value Log fold change p-value Log fold change p-value Log fold change p-value Log fold change
CHN1 6.10E-03 −1.61 < 0.01 −2.63 3.79E-02 −1.61
NSF 1.10E-02 −0.44 < 0.01 −3.23 7.74E-03 −1.15
SV2B 1.44E-02 −0.87 < 0.01 −2.50 4.79E-02 −1.20
GABARAPL1 2.59E-02 −0.73 < 0.01 −1.31 1.10E-02 −1.31
DCLK1 3.29E-02 −0.90 6.95E-03 −1.48
ATP6V1A 3.58E-02 −0.71 < 0.01 −3.33
Eight genes were identified as DE by PSEA and those that were also significantly DE in at least one independent study are included in the table. Fold changes and
p-values obtained were from the published manuscript where possible (Simunovic et al., 2010; Elstner et al., 2011) or generated from re analysis of raw data (Zheng
et al., 2010).
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NSF as novel candidate PD susceptibility gene in an Ashkenazi
Jewish population (Liu et al., 2011). SV2B was also decreased
in HD cortex neurons and DCLK1 was decreased in both HD
and PD cortex neurons, suggesting that these genes may be
involved in common pathways impacting neuronal degeneration
in HD and PD. GABARAPL1 is also decreased in PD putamen
neurons and is a key gene in the regulation of autophagy (see
below).
INTERESTING GENES AND PATHWAYS REPRESENTED IN THE PSEA
RESULTS
The largest numbers of differentially expressed genes identified
by our PSEA analyses in both HD and PD brains were in neuronal
cells, although differences were also found in other brain cell types
(astrocytes, oligodendrocytes and microglia). Annotation cluster
analyses of the PSEA results using DAVID (Huang Da et al., 2009)
and network analysis, employing both coregulation and PPI data,
identified a number of genes and biological processes that have
been implicated in neurodegenerative diseases.
Functional annotation cluster analyses in HD brain highlight
endosome and plasma membrane signaling pathways
Htt is known to have functions in protein trafficking, vesi-
cle transport, and postsynaptic signaling that may be altered
by the HD-causing mutation (Gil and Rego, 2008). DAVID
analyses of the genes detected as DE in HD neurons iden-
tified enrichment in genes related to vesicular transport and
protein localization (Table 3, Annotation cluster 2). These
included the endosomal Ras-related protein Rab-9B GTPase
(RAB9B), syntaxin 1B (STX1B), the secretory carrier membrane
protein 5 (SCAMP5), and the coiled-coil domain contain-
ing protein 91 (CCDC91). Interestingly, we have previously
observed DE of RAB9B in a mouse model of HD (Tang
et al., 2011). STX1B is essential for the regulation of sponta-
neous and evoked synaptic vesicle exocytosis (Mishima et al.,
2014) and has been associated with PD in GWAS studies
(Pihlstrom et al., 2013). SCAMP5 is involved in vesicle endocy-
tosis (Zhao et al., 2014) and has been associated with autism
(Castermans et al., 2010). CCDC91 is thought to be involved
in white matter development and maintenance (Sprooten et al.,
2014).
Annotation cluster 1 of neuronally DE genes in HD cor-
tex (Table 3) is characterized by genes with plasma membrane-
associated functions. This group includes G protein-coupled
receptor 176 (GPR176), ADAM metallopeptidase domain 23
(ADAM23), synaptic vesicle glycoprotein 2B (SV2B), andDCLK1,
but also RAB9B, STX1B and SCAMP5. Progressive abnormal-
ities in SV2 expression in skeletal muscle and neuromuscular
junctions have been previously reported in a mouse model of
HD (Ribchester et al., 2004). DCLK1 is involved in cortical
development (Sossey-Alaoui and Srivastava, 1999) and has been
associated with schizophrenia and attention deficit/hyperactivity
disorders (Havik et al., 2012). ADAM23 is a cell-cell adhesion
protein highly expressed in the nervous system (Goldsmith et al.,
2004) and suspected to regulate neuronal differentiation (Wang
et al., 2012).
Table 3 | David functional annotation clustering with differentially expressed genes in the motor cortex of HD brains (revealed by PSEA).
HD motor cortex
Category Term Count P-Value Fold Enrichment FDR
NEURONS
Annotation Cluster 1 Enrichment Score: 2.79
GOTERM_CC_FAT GO:0044459∼plasma membrane part 9/12 7.74E-05 4.35 0.07
GOTERM_CC_FAT GO:0005886∼plasma membrane 10/12 5.07E-04 2.82 0.47
GOTERM_CC_FAT GO:0005887∼integral to plasma membrane 6/12 1.97E-03 5.38 1.81
GOTERM_CC_FAT GO:0031226∼intrinsic to plasma membrane 6/12 2.18E-03 5.26 2.00
GOTERM_CC_FAT GO:0031224∼intrinsic to membrane 10/12 1.02E-02 1.94 9.08
GOTERM_CC_FAT GO:0016021∼integral to membrane 9/12 3.66E-02 1.81 29.17
NEURONS
Annotation Cluster 2 Enrichment Score: 1.78
SP_PIR_KEYWORDS transport 6/14 3.49E-03 4.94 3.54
GOTERM_BP_FAT GO:001619∼vesicle-mediated transport 4/12 9.81E-03 7.83 10.52
GOTERM_BP_FAT GO:0015031∼protein transport 4/12 2.09E-02 5.92 21.20
GOTERM_BP_FAT GO:0045184∼establishment of protein localization 4/12 2.14E-02 5.86 21.67
GOTERM_BP_FAT GO:0008104∼protein localization 4/12 3.07E-02 5.11 29.66
SP_PIR_KEYWORDS protein transport 3/14 4.12E-02 8.50 35.21
ASTROCYTES
Annotation Cluster 1 Enrichment Score: 1.86
GOTERM_BP_FAT GO:0008284∼positive regulation of cell proliferation 3/6 8.79E-03 16.34 10.35
GOTERM_BP_FAT GO:0030182∼neuron differentiation 3/6 9.80E-03 15.44 11.48
GOTERM_BP_FAT GO:0042127∼regulation of cell proliferation 3/6 3.00E-02 8.59 31.47
www.frontiersin.org January 2015 | Volume 8 | Article 441 | 7
Capurro et al. PSEA deconvolution
Functional annotation cluster analyses in PD brain find
mitochondrion-associated molecules
Within the PD datasets, genes encompassing a variety of functions
previously associated with PD were identified as DE, including
pathways common to a number of different neurodegenerative
diseases, such as HD and Alzheimer’s disease (AD) (Table S8,
Annotation cluster 4).
Functional annotation clustering analysis of genes DE in PD
cortical neurons exhibited the highest complexity of enriched
elements. Among these was an abundance of purine nucleotide
binding-related genes (Annotation clusters 1, and 3). The cortical
neuron purine binding nucleotide cluster comprises 26 DE genes,
including several tubulin genes (TUBB2A, TUBG1, TUBA1B).
Annotation clusters 2 and 5 include many terms associated with
microtubules and tubulin, reflecting that abnormalities in micro-
tubule dynamics have also been previously implicated in PD
(reviewed in Feng, 2006).
Several lines of evidence have jointly supported causal links
between changes in mitochondrial energetics and function and
neuron-specific degeneration in PD (Jin et al., 2006; Narendra
et al., 2008; Schapira, 2008; Van Laar and Berman, 2009).
Consistent with this idea, oxidative phosphorylation, mitochon-
drial biological processes and mitochondrial localization were
evident in the PD cortical neuron DE (Table S8, Annotation
cluster 4), being represented by the mitochondrial inner mem-
brane protein (IMMT), NADH dehydrogenase (ubiquinone) 1
subcomplex unknown-2 (NDUFC2) or cytochrome c oxidase
subunits 4 isoform 1 and 5a (COX4I1 and COX5A). Changes
in COX gene transcription has been purported to reflect cellu-
lar levels of oxidative stress (Roemgens et al., 2011) and affect
cytochrome C oxidase activity (Castello et al., 2008). Interestingly,
COX4I1 and COX5A were also found DE in the microglial PD
PSEA data (Table S4). Microglial cells are specialized phago-
cytes that react to neuronal injury or damage (Glass et al., 2010)
and can release neurotoxic reactive oxygen species under cer-
tain conditions (Block et al., 2007). Together with the fact that
dopaminergic neurons are more sensitive to oxidative stress com-
pared with other types of neurons (Block et al., 2007), changes
in cytochrome activity in neurons or microglia might have a
proximal effect on the development of PD (Chaturvedi and Beal,
2013).
Kinase genes, including selected mitogen-activated pro-
tein kinase-related genes (MAP2K1, MAP2K4, MAPK10), were
well-represented within neurons in the PD cortex (Table
S8 Annotation cluster 3). During neuronal injury various
MAPKs can be activated in relation with effects on cellu-
lar respiration, transport, release of reactive oxygen species,
mitophagy and apoptosis (Dagda et al., 2009). DE kinases also
included the calcium/calmodulin-dependent protein kinase II
beta (CAMK2B), known to important for synaptic plasticity
and memory (Shonesy et al., 2014) and a brain-enriched p21-
activated kinase (PAK7), as well as DCLK1.
Network analyses based on coregulation and protein-protein
interaction highlight autophagy-related DE genes in PD neurons
Analyses using publically available data of coregulation and PPIs
were undertaken to provide a complementary way to identify
functional groups of genes within lists of identified DE gene lists.
Coregulation of genes was used to initially construct DE gene net-
works, to which we added shared DE gene (protein) interacting
proteins to potentially identify common targets or regulators of
DE genes (proteins). Data from CNS cell-type-specific expression
data was also utilized. Together these approaches increased insight
into the nature of a given network’s function.
One particularly well-populated gene network, of DE genes
in PD putamen neurons, is illustrated in Figure 3. This net-
work shows strong representation of autophagy-related processes.
Autophagy is a highly evolutionarily conserved process carried
out by the endosomal-lysosomal system to regulate protein and
organelle turnover via targeted lysosomal degradation. There is
increasing evidence that abnormalities in autophagy may con-
tribute to neurodegeneration in HD, PD and AD (Lynch-Day
et al., 2012). In particular, many proteins related to PD have
specific roles in the regulation of autophagy and/or mitophagy
(the clearance of mitochondrial components by autophagy)
(reviewed in De Vries and Przedborski, 2013). There is clear
evidence that reduced autophagy can lead to PD-linked phe-
nomena including accumulation of α-synuclein, mitochondrial
dysfunction and neuronal death (reviewed in Zhang et al.,
2014).
The autophagy-related network illustrated in Figure 3 promi-
nently features GABARAPL1, an autophagy gene 8 (ATG8)
homolog, which was decreased in both the substantia nigra
and putamen in PD brains. GABARAPL1 is the most highly
expressed ATG8 homolog in the nervous system and it encodes
a key autophagy protein that associates with autophagic vesicles
(Chakrama et al., 2010). Its expression is limited to neuronal
cells, and it is particularly highly expressed in the substantia
nigra pars compacta, the region most affected by Parkinson’s
disease (Le Grand et al., 2013). In the neuronal putamen DE
gene network, GABARAPL1 expression was coregulated with
another highly expressed neuronal gene, Malate Dehydrogenase
1, NAD (MDH1). MDH1 is important in transporting NADH
equivalents across the mitochondrial membrane and also inter-
acts with the ubiquitin ligase PARKIN, encoded by PARK2
(Cookson, 2012; Scarffe et al., 2014). PARKIN is known to
work together with PINK1 to promote mitophagy (Scarffe et al.,
2014). Another mitochondrial gene, brain expressed, X-linked 1
(BEX1) (Xiao et al., 2014) interacts with the p75 neurotrophin
receptor (Vilar et al., 2006) and is upregulated in axonal injury
(Khazaei et al., 2010). Other genes in this network also play
roles in synaptic vesicle exocyotosis [Regulator Of G-Protein
Signaling 7 (RGS7)], regulation of apoptosis [Thymocyte Nuclear
Protein 1 (THYN1/THY28) and Modulator of apoptosis protein
1 (MOAP1)] (Toyota et al., 2012), and α-synuclein aggrega-
tion [Secretogranin V (7B2 Protein) (SCG5)] (Helwig et al.,
2013). Moreover, the protein products of 7 of the 11 genes in
the putamen DE list interact with Ubiquitin (UBC) [Biogrid
(http://thebiogrid.org/)]. GABARAPL1 and TSPYL1 proteins
both interact with sirtuin 1 (SIRT1), a NAD-dependent deacety-
lase attributed with neuroprotecive activities in PD, AD, and HD
(reviewed in Herskovits and Guarente, 2014), which is required
for resveratrol-mediated induction of autophagy (Wu et al.,
2011).
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FIGURE 3 | Network analysis of differentially expressed neuronal genes
in the putamen in PD indicates autophagy modulation. Expression
coregulation data, PPIs and gene expression levels in mouse neuronal cells
strongly implicates the mammalian neuronal specific ATG8 homolog
GAPARAPL1 and other vesicle associated genes in the regulation of
autophagy in the putamen in PD. Blue borders indicate nodes for
genes/proteins that were DE in PD putamen neurons. With the exception of
TSPYL1, all were identified as decreased in PD compared to controls. Nodes
without a blue border were introduced into the network due to evidence of
common human PPIs with at least two DE genes. Gene expression
coregulation within human frontal cortex (Mistry et al., 2013) is indicated by
dashed green edges and PPIs are indicated by solid magenta edges. The
centers of the nodes are also shaded by normalized translational ribosomal
affinity profiling expression levels (TRAP) from eight different murine
neuronal cell populations (Doyle et al., 2008). The neuronal populations are
(clockwise from top); cortical Cck neurons, cortical Cort interneurons, striatal
Drd1 medium spiny neurons, striatal Drd2 medium spiny neurons, cortical
Etv1 corticostriatal neurons, corticospinal Glt25d2 neurons, cortical
Ntsr1corticothalamic neurons, and cortical Pnoc interneurons. Gray indicates
low expression and black high expression.
Notably, 6 of the 11 genes decreased with PD in neurons within
the putamen are also decreased in PD cortical neurons (BEX1,
ATP6V1E1, RGS7, MDH1, THYN1, MOAP1). There were also
expression changes shared between the putamen and substan-
tia nigra, including the decreased expression of the autophagy-
related gene GABARAPL1 and lysosome H+ transporting ATPase
subunits (ATP6V1E1 and ATP6V1A in putamen and substan-
tia nigra respectively). There were also trends toward DE of
MDH1 (p = 0.06), MOAP1 (p = 0.113), and BEX1 (p = 0.232)
in the substantia nigra. It is also noteworthy that SNARE and
NSF proteins (found decreased by PSEA and in LMD studies
of PD substantia nigra neurons, see above) have been recently
implicated in autophagy (Moreau et al., 2013) in addition to
their better characterized function of being essential for vesicular
fusion at the plasma membrane (Sudhof, 1995).
SUMMARY AND CONCLUSIONS
Our study has further demonstrated the applicability and utility
of PSEA to refine analyses of interesting human disease datasets.
These further demonstrate the technical soundness of the method
and show solutions for applying PSEA in cases where mod-
eling all resident cell populations simultaneously is unfeasible.
Most importantly, we show how PSEA can be applied to gener-
ate and refine hypotheses regarding the etiopathology of human
neurological disorders, thereby contributing to the larger efforts
to find new therapies. Our PSEA analyses were able to bring cell-
type-specific disease pathways into view in this study. Findings
in PD neurons supported the growing evidence that autophagy
is an important aspect of PD etiology and identify additional
potential contributors to autophagic and mitophagic dysfunc-
tion. Together with the identification of NSF as a candidate PD
susceptibility gene our data suggest NSF as a strong candidate
for further analysis. In HD neurons, both expected and novel
facets of endosomal and plasma membrane signaling processes
showed dysregulation. Moreover, the fact DCLK1 was detected
as DE in both HD and PD neurons indicates that its potential
involvement in neurodegenerative processes should be carefully
considered.
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It will be interesting in subsequent work to apply PSEA to
other diseases and tissues. Moreover, we look forward to applying
it to other data types, such as proteomic or metabolomic data, in
which complementary insights into disease-related processes can
be detected.
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